Cancer Genetics is an esteemed peer-reviewed journal dedicated to advancing the field of cancer research through the lens of genetics. Published by Elsevier Science Inc and available in both print (ISSN: 2210-7762) and online (E-ISSN: 2210-7770), this journal aims to provide a platform for the dissemination of high-quality studies that unravel the genetic underpinnings of cancer. Since its inception in 2011, Cancer Genetics has become a significant resource for researchers, professionals, and students with a shared interest in understanding the intricate relationship between genetics and oncogenesis. With an impact factor that reflects its influence, the journal has maintained a Q3 ranking in Cancer Research, Genetics, and Molecular Biology as of 2023, indicating its growing importance in these fields. Additionally, the journal offers open access options to ensure that crucial findings are easily accessible to the global research community. By bridging the gap between genetics and cancer studies, Cancer Genetics plays a pivotal role in fostering innovation and collaboration among scientists and clinicians striving to improve cancer diagnosis and treatment.

BULLETIN DU CANCER is a pivotal academic journal dedicated to the field of oncology, providing a platform for innovative research and insights into cancer treatment and diagnostics. Published by Elsevier Masson, Corp Off in France, this journal has been a part of the scientific community since 1966, and is committed to sharing critical findings that influence clinical practices and improve patient outcomes. Despite its recent rankings placing it in the Q4 category for Cancer Research and Q3 for Hematology and other related fields, BULLETIN DU CANCER remains essential for those interested in the latest developments in cancer biology and treatment methodologies. With an emphasis on both basic and clinical research, it serves as a valuable resource for researchers, healthcare professionals, and students seeking to deepen their understanding in various dimensions of oncology. This journal is particularly relevant as it continues to spotlight emerging research trends and supports the global imperative to combat cancer more effectively.

MUTAGENESIS, published by Oxford University Press, is a leading journal in the fields of genetics, toxicology, and health, dedicated to advancing our understanding of mutagenic processes and their implications for human health. With an ISSN of 0267-8357 and an E-ISSN of 1464-3804, this journal has been at the forefront of mutagenesis research since its inception in 1986 and will continue to publish cutting-edge studies until 2024. Holding an impressive position in the academic community, MUTAGENESIS is ranked Q2 in Genetics, Q2 in Clinical Genetics, Q2 in Health, Toxicology, and Mutagenesis, and Q1 in Toxicology, reflecting its commitment to high-quality scholarly work. The journal enjoys a robust global readership, with significant rankings in various Scopus categories, including top positions in Environmental Science and Clinical Genetics, ensuring that it remains a vital resource for researchers, professionals, and students alike. While access to its articles is not completely open, MUTAGENESIS provides valuable insights that fuel innovative research and drive forward the understanding of genetic risks and toxicological assessments.

Oncology Research and Treatment, published by KARGER, is a highly regarded academic journal dedicated to advancing the field of oncology through rigorous research and clinical insights. With a history spanning from 1978 to 1997 and continuing from 2013 to 2024, this journal provides a vital platform for researchers and professionals in cancer research, hematology, and related disciplines. Though currently listed in the Q3 tier of 2023 for Cancer Research, Hematology, and Oncology, its growing readership and open access policy enhance its visibility and impact within the scientific community. Based in Switzerland, the journal features diverse access options, reflecting the global importance of oncology research. With a focus on innovative treatments and the latest methodologies, Oncology Research and Treatment plays a crucial role in fostering collaboration and dialogue among researchers, professionals, and students alike, helping to shape the future of cancer care and management.

JOURNAL OF MEDICAL GENETICS, published by the BMJ PUBLISHING GROUP, stands as a premier platform in the field of genetics, focusing on both fundamental genetic research and its clinical applications. With a distinctive legacy dating back to 1965 and a significant role in advancing the understanding of genetic disorders, this journal has established itself in the top tiers with a commendable Q1 category ranking in both Genetics and Clinical Genetics as of 2023. The journal's impact is underscored by its Scopus rankings, placing it among the leading journals in the fields of medicine and genetics. Researchers and practitioners are drawn to its rigorous peer-review process and its commitment to disseminating high-quality research findings, critical reviews, and innovative clinical practices. While it is not an open-access journal, the insights provided are invaluable for anyone looking to deepen their knowledge or contribute to the burgeoning field of medical genetics.

Cancer Causes & Control, an esteemed journal within the field of Cancer Research and Oncology, is published by SPRINGER. Since its inception in 1990, this journal has dedicated itself to exploring the complex interplay between environmental, genetic, and lifestyle factors that contribute to cancer causation and control, aiming to inform public health initiatives and improve cancer prevention strategies. With an impressive Q2 rank in both its categories, the journal serves as a vital resource for researchers, professionals, and students seeking insights into the latest findings and methodologies in cancer epidemiology. Although there is no Open Access option, researchers can access valuable articles that reflect rigorous peer review and significant contributions to the field. The journal’s commitment to advancing knowledge related to cancer risks and management makes it an essential platform for disseminating impactful research and fostering collaboration among scholars worldwide.

The EUROPEAN JOURNAL OF HUMAN GENETICS, published by SpringerNature, stands as a preeminent platform in the field of genetics and clinical genetics. Established in 1993, this prestigious journal, with an ISSN of 1018-4813 and an E-ISSN of 1476-5438, has consistently maintained its position in the Q1 quartile for both Genetics and Clinical Genetics categories as of 2023, reflecting its significant contributions to the field. Its impact is further underscored by its impressive Scopus rankings, placing it in the 92nd percentile among clinical genetics journals. The journal aims to disseminate cutting-edge research, case studies, and reviews that advance our understanding of human genetics, promoting collaboration and innovation among researchers, professionals, and students alike. While it does not currently offer open access, the journal provides substantial value through its rigorous peer review process and commitment to quality. As it continues to shape the future of genetic research through 2024 and beyond, the EUROPEAN JOURNAL OF HUMAN GENETICS remains an essential resource for those dedicated to exploring the complexities of human heredity.

Breast Cancer is a prestigious peer-reviewed journal published by SPRINGER JAPAN KK, specializing in the multifaceted domains of oncology and medical pharmacology. With an impressive impact factor and recognized within the Q1 category in multiple areas, including Medicine (miscellaneous), Radiology, and Nuclear Medicine and Imaging, this journal serves as a fundamental resource for cutting-edge research and clinical advancements in breast cancer treatment and care. Its indexed presence in renowned databases like Scopus further affirms its significance, ranking 56th in Radiology and 60th in Pharmacology. The journal aims to bridge the gap between clinical practice and scientific research by publishing original articles, reviews, and case studies that enhance understanding and improve patient outcomes. With converged content available from 1994 to 2024, the journal is dedicated to fostering innovative research while engaging a global audience of researchers, clinicians, and students passionate about tackling breast cancer challenges.

Application of Clinical Genetics is a premier open-access journal published by Dove Medical Press Ltd., dedicated to advancing the field of clinical genetics since its inception in 2008. Based in New Zealand, this journal has established itself as a significant resource for researchers, clinicians, and students alike, contributing to the body of knowledge in both genetic medicine and clinical applications. With an impact factor reflecting its contributions to the field, the journal holds positions in the Q2 and Q3 quartiles of the 2023 Genetics categories, showcasing its relevance and scientific merit. Furthermore, it ranks #43 out of 99 in Clinical Genetics and #153 out of 347 in Biochemistry, Genetics, and Molecular Biology, indicating robust performance amongst its peers. The journal’s broad scope, encompassing various aspects of clinical genetics, ensures that it remains at the forefront of critical discussions, innovative research, and applications essential for the progression of personalized medicine. Researchers and professionals are encouraged to explore its openly accessible content that fosters collaboration and the sharing of knowledge in this dynamic and rapidly evolving field.

CANCER INVESTIGATION is a distinguished peer-reviewed journal published by Taylor & Francis Inc, dedicated to the advancing field of cancer research and oncology. With an ISSN of 0735-7907 and E-ISSN of 1532-4192, this journal has been a pivotal resource for professionals and researchers since its inception in 1983, continually contributing to the evolving landscape of cancer investigation until its convergence in 2024. CANCER INVESTIGATION boasts noteworthy rankings in 2023, including Q3 in Cancer Research and Q2 in Medicine (miscellaneous), highlighting its relevance and impact in these critical areas. The journal's commitment to disseminating innovative research and comprehensive reviews makes it an essential platform for those engaged in cancer studies and related disciplines. While currently not available as an open-access publication, CANCER INVESTIGATION remains an invaluable tool for understanding the complexities of cancer, offering insights that drive scientific advancements and improve patient outcomes.